Specifications TableSubjectEmergency MedicineSpecific subject areaEpistaxisType of dataTable\
GraphHow data were acquiredA standardized form was completed by treating physician. For details, see the attached 'Data Collection Form' in supplementary material.Data formatRaw and analysedParameters for data collectionPatients presenting to the emergency department with acute anterior epistaxis that met all inclusion criteria with written informed consent were included. Patients presenting on odd numbered days of the month were assigned to the oxymetazoline treatment group while patients presenting on even numbered days of the month were assigned to the TXA group.Description of data collectionPatients were assessed for hemostasis after treatment administration at 10, 15, 20, 25 and 30 minutes. If hemostasis was not achieved at 30 minutes, the protocol was aborted, and the second line treatment was chosen by the treating physician. Patients were contacted at 48 hours after discharge for any recurrence of bleeding.Data source locationLakeland Health\
1234 Napier Avenue\
Saint Joseph, MI, USAData accessibilityData incorporated within the articleRelated research articleKristen Whitworth, Comparative Effectiveness of Topically Administered TXA Versus Topical Oxymetazoline Spray for Achieving Hemostasis in Epistaxis, Journal of Emergency Medicine, Article in Press**Value of the Data**•This dataset compares the effectiveness of the topical application of the intravenous formulation of TXA to the standard of care, oxymetazoline, in achieving hemostasis in acute epistaxis.•The data can be useful for physicians treating patients with acute epistaxis to avoid escalation of treatment to more invasive modalities which can increase discomfort, risk for complications, and time in the emergency department.•This dataset could supplement future investigations on the effectiveness of using TXA in the treatment of acute epistaxis.

1. Data description {#sec1}
===================

This dataset was collected from a standardized form (see 'Data Collection Form' included in supplemental material) completed by the treating physician for each patient included in this investigation. The raw data regarding each patient is displayed in [Table 1](#tbl1){ref-type="table"} including the age and gender of each patient, prescription for antiplatelet or anticoagulant medications, time to hemostasis, occurrence of rebleeding in the emergency department or at 48 hours, and the second line treatment chosen if hemostasis was not achieved. Tables displaying the analysis of patient characteristics, primary outcomes, secondary outcomes, and second line treatments can be found in the original research article \[[@bib1]\].Table 1Raw data collected from standardized forms completed by the treating physician for both treatment groups.Table 1Treatment GroupAge (Years)SexAnticoagulant or Antiplatelet TherapyHemostasis AchievedTime to Hemostasis (minutes)Rebleed in the EDRoom to Dispo (minutes)Rebleed at 48 HoursTreatment for Failure or Return VisitTXA43Fnoneyes10yes151n/a4% cocaine50Fnoneyes10no92no79Fwarfarinnon/an/a119n/aNasal Packing73Maspirinyes10no55no46Mnoneyes10no109no75Maspirinyes15no121no72Mnoneyes45no87no74Mwarfarinyes15no104no84Maspirinyes35no98no77mnoneyes15no86no62Mnoneyes15no108no85Fnonenon/an/a126n/aNasal Packing101Fclopidogrel, aspirinnon/an/a140n/aOxymetazoline70Fnoneyes10no55no70Mapixaban, aspirinyes15no119no62Fnoneyes25yes90n/aNasal Tampon84Fwarfarin, aspirinyes20no160yesNasal Tampon78Fclopidogrelnon/an/a64n/aNasal TamponOxymetazoline88Fapixabannon/an/a129n/aNasal Tampon63Fclopidogrelnon/an/a178n/aNasal Tampon73Mrivaroxabanyes15no106yesNasal Tampon50Mnonenon/an/a136n/aNasal Tampon51Fwarfarinnon/an/a162n/aNasal Tampon63Fnoneyes15no82yesNasal Tampon84Fwarfarinnon/an/a76n/aSilver Nitrate69Maspirinyes10no79no70Mprasugrelnon/an/a131n/aNasal Tampon, Admission, ENT Consult71Mrivaroxabannon/an/a172n/aNasal Tampon62Faspirinnon/an/a116n/aNasal Tampon65Mdabigatrannon/an/a267n/aNasal Tampon27Mnoneyes30no115no86Mwarfarinnon/an/a145n/aNasal Packing71Faspirinnon/an/a77n/aPressure77Fapixaban, aspirinnon/an/a162n/aNasal Tampon74Faspirinnon/an/a237n/aNasal Tampon50Fclopidogrelyes15no105no75Mwarfarinyes15no119no48Fclopidogrel, aspirinyes15no148no

2. Experimental design, materials, and methods {#sec2}
==============================================

This was a prospective collection of data on patients presenting to the emergency department with the chief complaint of epistaxis between January 2016 and January 2018. Patients were enrolled in two community emergency departments, both associated with an emergency medicine residency program. Patients over the age of 18 years were included if they presented to the emergency department with new or acute anterior epistaxis. Exclusion criteria included patients who were pregnant or breast feeding, non-postmenopausal women, patients with surgery to the nose or pharynx within the past three months, concomitant facial injuries from trauma, a history of hemophilia, a blood pressure over 200/120 mmHg or a known allergy to TXA or oxymetazoline. Patients with posterior epistaxis were also excluded from data collection. The determination of posterior epistaxis was made if the patient had blood in the posterior oropharynx on examination after the nasal passages were cleared of blood clots. Patients prescribed oral anticoagulants were not excluded, as a large majority of the patient population were taking these medications. However, the form of anticoagulation (i.e.: aspirin, platelet inhibitors, warfarin, novel factor Xa inhibitors) were noted in patients\' charts and documented on the standardized form.

Eligible patients were allocated into two separate treatment groups: topical oxymetazoline or topical application of the intravenous formulation of TXA. Patients presenting on odd numbered days of the month were assigned to the oxymetazoline treatment group while patients presenting on even numbered days of the month were assigned to the TXA group. Prior to application of the assigned drug, the patient was instructed to clear nasal passages of blood clots by blowing his or her nose. Next, suction was applied to affected nare to clear any clots not cleared initially. The treatment drug was then applied to affected nasal passage via aerosolization. The TXA group received 3 mL of intravenous TXA 1000 mg/10 mL through an atomizer in the affected nare. The oxymetazoline group received three sprays of oxymetazoline hydrochloride 0.05% in the affected nare from a standardized 30mL bottle. After application of the topical drug, direct pressure was applied over the cartilaginous portion of the nasal bridge with patient\'s fingers. The patient was instructed to pinch the area firmly after the proper amount of pressure was demonstrated by the treating physician. Neither the patient nor the physician was blinded to the treatment group due to the differences in the modes of administration of the medications, as TXA was administered through an automizer and oxymetazoline through aerosolized sprays from a standard bottle. The physician assessing the outcome of the treatment was the same individual that administered the treatment drug and therefore was not blinded either. This physician was responsible for completing the standardized form.

Assessment for ongoing bleeding was performed at 10, 15, 20, 25 and 30 minutes after drug administration and application of pressure on the nose. At 30 minutes, if hemostasis had not been achieved, the protocol was aborted, and the physician was left to treat at their own discretion. Patients were contacted by phone by the principal investigator 48 hours after discharge to document any rebleeding.
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The following are the Supplementary data to this article:Multimedia component 1Multimedia component 1Multimedia component 2Multimedia component 2

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.dib.2020.105283>.
